↑ Rising
Health
🔮 fades
Can GLP-1s heal the brain? Obesity drugs get a makeover for addiction and depression
Obesity drugs get a makeover for addiction and depression
Obesity
57 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Obesity
This hub groups 57 separate news trends connected to Obesity, spanning June 18, 2026 through October 14, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 416 article observations and 394 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
▲ Peaking
Business
🔮 fades ✓
Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal
Roche licenses obesity therapy from China's Rona in major deal
◼ Archived
Health
🔮 fades ✓
New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial
Injections target dangerous belly fat, but with a twist.
◼ Archived
Health
🔮 fades ✓
People With Dementia May Actually Live Longer if They Carry Extra Weight
7 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Nagging people to eat healthily does not work
Nagging people to eat healthily is ineffective, according to recent studies and guidelines.
◼ Archived
Health
🔮 fades ✓
Some who take GLP-1s are suffering serious side effects, but it's unclear how often
Some who take GLP-1s are suffering serious side effects, but it's unclear how often.
◼ Archived
Health
🔮 fades ✓
Scientists uncover a clue that could hint at why we regain weight after diets
A $4 million study is underway to unravel why weight returns after stopping GLP-1 drugs.
◼ Archived
Health
🔮 fades ✓
Novel Injectable Drug Cuts Visceral Fat in Phase 2 Trial
Injectable CBL‑514 slashes visceral fat in a Phase 2 trial, sparking fresh debate on non‑surgical obesity solutions.
◼ Archived
Health
🔮 fades ✓
Time-restricted eating boosts weight loss in adults with obesity, prediabetes
Eight‑hour time‑restricted eating drives weight loss in obese adults with prediabetes without cutting calories
◼ Archived
Business
🔮 fades ✓
The Next Frontier for Obesity Drugs Isn’t How Much Weight You Lose, but What Kind
9 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
GLP-1s shift from 'patients' to 'customers' as weight loss trend surges
◼ Archived
Health
🔮 fades ✓
Is long-term use of GLP-1s safe?
13 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Nearly 1 in 6 Kids on GLP-1s Developed This Problem Within a Year
Study finds link between GLP-1 drugs and nutritional deficiencies in children
◼ Archived
Business
🔮 fades ✓
‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
Massachusetts man shares sudden blindness journey after taking GLP-1, sparking lawsuits and safety concerns.
◼ Archived
Business
🔮 fades ✓
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
700,000 seniors start GLP-1 treatments under Medicare, with 70% on Eli Lilly drugs
◼ Archived
Health
🔮 fades ✓
Millions of parents are taking GLP-1s. How should they talk to their kids about it?
GLP-1s linked to nutritional deficiencies in nearly 1 in 6 children, raising questions about parental conversations.
◼ Archived
Business
🔮 fades ✓
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
Novo Nordisk sheds its historic suffix to chase the booming obesity‑treatment market.
◼ Archived
Health
🔮 fades ✓
A Startling Percentage Of Americans Have Fatty Liver Disease
7 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement
New era of obesity medicines raises hopes for broader health benefits beyond weight loss.
◼ Archived
Health
🔮 fades ✓
PCOS has a new name, because it was never just about the ovaries
PCOS is being renamed PMOS to highlight its broader metabolic roots, sparking debate over its meaning for fertility.
◼ Archived
Health
🔮 fades ✓
Weight regain after obesity drugs tied to higher odds of suicidal thoughts in observational study
Weight regain after obesity drugs spikes risk of suicidal thoughts, study finds
◼ Archived
Health
🔮 fades ✓
GLP-1 prescriptions for kids up more than 30,000% since 2019
GLP-1 prescriptions for kids surge by over 30,000% since 2019
◼ Archived
Health
🔮 fades ✓
Scientists Say a Key Trigger for Alzheimer’s Damage Isn’t Even in the Brain
8 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Don’t take GLP-1s? Be prepared to explain yourself.
A surge in GLP‑1 prescriptions turns personal weight‑loss choices into a public debate demanding explanations.
◼ Archived
Health
🔮 fades ✓
New weight-loss compound melts fat without curbing appetite
A new weight-loss drug promises to melt fat without suppressing appetite or causing muscle loss.
◼ Archived
Health
🔮 fades ✓
I lost the weight on a GLP-1
Men’s weight‑loss drugs face a double‑edge of stigma and rebound fears as GLP‑1 use spikes.
◼ Archived
Health
The middle-aged disease that makes you feel tired and often goes undiagnosed
A rise in liver disease among younger adults and those with diabetes is sparking concern among health professionals.
◼ Archived
Health
Is the US seeing a turning point in obesity rates?
New research and drugs are challenging long-held beliefs about weight loss and obesity in the US.
◼ Archived
Business
🔮 fades ✓
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
◼ Archived
Health
New weight loss drug may burn fat without muscle loss seen in GLP-1 drugs
A new weight loss drug may burn fat without the muscle loss seen in GLP-1 drugs.
◼ Archived
Health
🔮 fades ✓
Promising new weight loss and diabetes treatment helps burn fat while keeping muscle in preclinical study
A new treatment could revolutionize weight loss and diabetes management by targeting fat while preserving muscle.
◼ Archived
Health
🔮 fades ✓
Could GLP-1s help with alcohol use disorder? A Philly VA doctor is leading a national trial to find out.
A national trial is exploring whether GLP-1s, known for weight loss, can also help with alcohol use disorder.
◼ Archived
Health
🔮 fades ✓
Why Three Minutes Of Sprinting May Beat An Hour+ Spent Exercising
A 3-minute sprinting routine may offer health benefits comparable to an hour of moderate exercise.
◼ Archived
Health
🔮 fades ✓
Your waistline could reveal a hidden heart risk your BMI misses, major study finds
A major study suggests waist size may better predict heart disease risk than BMI.
◼ Archived
Health
🔮 fades ✓
GLP-1s May Be Working in an Entirely Different Way Than We Thought
New research suggests that popular weight-loss drugs may work differently than previously understood.
◼ Archived
Health
Supercharged by Social Media, the GLP-1 Boom Is Warping Teen Psyches
GLP-1 drugs are transforming teen attitudes toward obesity and body image, driven by social media.
◼ Archived
Health
🔮 fades ✓
Lilly's weight-loss pill gets UK regulator's nod
The UK has approved a new weight-loss pill, marking a significant shift in obesity treatment options.
◼ Archived
Health
‘Three decades of failure’: 7.2 million more adults now obese despite 14 government strategies
Despite 30 years of government strategies, obesity rates in England have doubled, leaving 14 million adults affected.
◼ Archived
Business
🔮 fades ✓
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
◼ Archived
Health
🔮 holds ✗
GLP-1 use tied to obesity decline, but doctors warn of alarming misuse
GLP-1 drugs are linked to a decline in obesity, but doctors are raising alarms about misuse.
◼ Archived
Health
GLP-1 weight loss drugs: What experts say about keeping weight off after stopping
Weight loss drug usage has reached a record high in the U.S. as medical professionals debate the long-term implications of GLP-1 therapy.
◼ Archived
Health
🔮 fades ✓
One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access
One in eight U.S. adults now utilizes GLP-1 drugs as Medicare expands coverage for weight-loss treatments.
◼ Archived
Health
🔮 fades ✓
Where You Carry Your Body Fat Is Directly Linked to Brain Aging in First-of-Its-Kind Study
New research indicates a direct link between the location of body fat and the rate of brain aging and memory loss.
◼ Archived
Business
🔮 fades ✓
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is advancing toward a 2027 regulatory filing for retatrutide following successful Phase 3 obesity trial results.
◼ Archived
Health
🔮 holds ✗
GLP-1 use rising rapidly among US adolescents and young adults, study finds
GLP-1 weight-loss medications are seeing a rapid surge in use among U.S. adolescents and young adults.
◼ Archived
Health
🔮 fades ✓
More young women in their 20s are getting type 2 diabetes
Health officials are warning of a 'health time bomb' as Type 2 diabetes cases surge among women in their 20s and those under 40.
◼ Archived
Health
🔮 fades ✗
An avocado a day reduces bad cholesterol particles, heart disease risk in adults with obesity, study says
New findings suggest that daily avocado consumption may lower bad cholesterol and heart disease risk for adults with obesity.
◼ Archived
Health
🔮 fades ✓
This GLP-1 retreat changed how I think about weight loss
GLP-1 medications are sparking broader conversations about weight loss retreats, medical benefits beyond weight, and the psychological impact of stigma.
◼ Archived
Health
🔮 fades ✓
Too many Britons are too fat to work
A new study reveals that over 600,000 people in the UK are unable to work due to obesity.
◼ Archived
Health
🔮 fades ✓
GLP-1’s Reduce Binge Eating Symptoms
Research suggests GLP-1 medications like Ozempic and Wegovy may provide a promising treatment for binge eating disorder.
◼ Archived
Health
🔮 fades ✓
Scientists Develop a Food Ingredient That May Prevent Obesity
The EU has approved a new dietary fiber additive designed to slow weight gain and help prevent obesity.
◼ Archived
Business
🔮 fades ✗
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
GLP-1 weight loss drugs are being used by a record number of Americans.
◼ Archived
Health
🔮 fades ✓
About 170,000 people in England expected to die from obesity-linked heart conditions by 2035
New research warns of a grim future for England's heart health due to rising obesity rates
◼ Archived
Health
🔮 fades ✓
The negative impacts of fruit juices and other sugary treats for children
Recent studies highlight the long-term health risks of sugary beverages for children.
◼ Archived
Health
🔮 fades ✓
Research shows weight-loss drugs may also reduce cancer risk
New research indicates GLP-1 receptor agonists used for weight loss may be linked to a reduced risk of certain cancers, specifically breast cancer.
◼ Archived
Health
🔮 fades ✓
The "dad bod," explained by science
Recent scientific analysis examines the 'dad bod' and how paternal obesity and diet impact the long-term health of children.
◼ Archived
Health
🔮 fades ✓
Ozempic users may be making a major weight-loss mistake, new study suggests
New research indicates a trend of decreased physical activity among individuals using GLP-1 weight loss medications like Ozempic and Wegovy.